AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12672710 — intervention group
Group type: COMPARATOR
Intervention: 500 mg oral calcium load with serum 25OHD at 50 nmol/L
Number of subjects: 2
Study 10819857 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (6.75 mg intravenous bolus, 300 microg/min for 3 hours, then 100 microg/min intravenously)
Number of subjects: 247
Study 10819857 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine (0.10‐0.35 mg/min intravenously)
Number of subjects: 247
Study 10819857 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 247
Study 10819857 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 247
Study 10819857 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban and Ritodrine
Number of subjects: 247
Study 9289703 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal gammapathy
Number of subjects: 82
Study 9289703 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyclonal gammapathy
Number of subjects: 82
Study 9289703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell immunity
Number of subjects: 82
Study 9289703 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell count (CD2+ and CD3+)
Number of subjects: 82
Study 9289703 — intervention group
Group type: EXPERIMENTAL
Intervention: T helper cells (CD4+)
Number of subjects: 82
Study 9289703 — intervention group
Group type: EXPERIMENTAL
Intervention: T suppressor cells (CD8+)
Number of subjects: 82
Study 9289703 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient life time
Number of subjects: 82
Study 9289703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cause of death
Number of subjects: 82
Study 1869345 — intervention group
Group type: EXPERIMENTAL
Intervention: Test preparation (sulpiride 200 mg)
Number of subjects: 16
Study 1869345 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (sulpiride 200 mg)
Number of subjects: 16
Study 6651313 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 51
Study 6651313 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 51
Study 3160869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (HD-MPA) 1200 mg p.o., b.i.d.
Number of subjects: 87
Study 3160869 — intervention group
Group type: COMPARATOR
Intervention: Mepitiostane (MS) p.o., b.i.d.
Number of subjects: 87
Study 3160869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (HD-MPA)
Number of subjects: 87
Study 3160869 — intervention group
Group type: COMPARATOR
Intervention: Mepitiostane (MS)
Number of subjects: 87
Study 29247351 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CCTA) during office hours
Number of subjects: 118
Study 29247351 — intervention group
Group type: COMPARATOR
Intervention: Coronary CT angiography (CCTA) outside office hours
Number of subjects: 118
Study 27627109 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (lipopolysaccharide endotoxin)
Number of subjects: 8
Study 24325365 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation, 100 mg administered three times at 6-h intervals
Number of subjects: 50
Study 24325365 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) formulation, 300 mg administered once to fasting subjects
Number of subjects: 50
Study 24325365 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) formulation, 300 mg administered once to fed subjects
Number of subjects: 50
Study 24325365 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CR to IR
Number of subjects: 50
Study 24325365 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of fasting to fed for CR
Number of subjects: 50
Study 21883710 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotic therapy (n=10)
Number of subjects: 20
Study 21883710 — intervention group
Group type: COMPARATOR
Intervention: No prior antibiotic therapy (n=10)
Number of subjects: 20
Study 20545703 — intervention group
Group type: EXPERIMENTAL
Intervention: NNF
Number of subjects: 43
Study 20545703 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 18313905 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel lipid formulation containing fenofibrate in omega‐3 oil
Number of subjects: 0
Study 18313905 — intervention group
Group type: COMPARATOR
Intervention: Tricor (current marketed product)
Number of subjects: 0
Study 16389915 — intervention group
Group type: EXPERIMENTAL
Intervention: Exact tests for one sample correlated binary data
Number of subjects: 0
Study 12950522 — intervention group
Group type: COMPARATOR
Intervention: Etilefrine
Number of subjects: 4
Study 12950522 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 4
Study 12950522 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac pacing
Number of subjects: 4
Study 12950522 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocking drugs
Number of subjects: 4
Study 10325264 — intervention group
Group type: EXPERIMENTAL
Intervention: Premutation carriers
Number of subjects: 51
Study 10325264 — intervention group
Group type: COMPARATOR
Intervention: Full mutation carriers
Number of subjects: 51
Study 10325264 — intervention group
Group type: COMPARATOR
Intervention: Unaffected controls
Number of subjects: 51
Study 7793549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nellcor N200 oximeter
Number of subjects: 36
Study 7793549 — intervention group
Group type: EXPERIMENTAL
Intervention: Datex Satlite DS103 oximeter
Number of subjects: 36
Study 2031913 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectal electromanometry in patients with NID
Number of subjects: 737
Study 7031855 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit influenza vaccine (A/Victoria/75 and B/Hongkong/73)
Number of subjects: 0
Study 7031855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30722039 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Sleep Restriction (CSR)
Number of subjects: 26
Study 30722039 — intervention group
Group type: COMPARATOR
Intervention: Control (8 hours sleep opportunity)
Number of subjects: 26
Study 29750900 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (20Hz) neuronavigated-rTMS sessions
Number of subjects: 80
Study 27053642 — intervention group
Group type: EXPERIMENTAL
Intervention: Imitation-based speech therapy for 6 weeks
Number of subjects: 19
Study 24346608 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine with adjunctive personalized treatments (APTs)
Number of subjects: 482
Study 24346608 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium with adjunctive personalized treatments (APTs)
Number of subjects: 482
Study 23013369 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing R95 activated carbon respirators
Number of subjects: 44
Study 20171653 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (4 mg) for 3 months
Number of subjects: 200
Study 20171653 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo) for 3 months
Number of subjects: 200
Study 17517005 — intervention group
Group type: EXPERIMENTAL
Intervention: Training parents in mediation procedures
Number of subjects: 48
Study 17517005 — intervention group
Group type: COMPARATOR
Intervention: Normal parental intervention
Number of subjects: 48
Study 16366762 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (30 mg sustained release nightly plus 15 mg immediate release 2 hr before cocaine infusion)
Number of subjects: 12
Study 16366762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11064229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention including skill training for providers, environmental orchestration (posters in clinical areas, DV questions on health questionnaires), and measurement and feedback.
Number of subjects: 5
Study 11064229 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 5
Study 9218198 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of verapamil and trandolapril
Number of subjects: 0
Study 9218198 — intervention group
Group type: COMPARATOR
Intervention: Verapamil alone
Number of subjects: 0
Study 9218198 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril alone
Number of subjects: 0
Study 9218198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8233530 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% guanethidine monosulphate
Number of subjects: 39
Study 8233530 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 39
Study 8233530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (guanethidine and water)
Number of subjects: 39
Study 3541653 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention program
Number of subjects: 0
Study 3541653 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31959609 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV vaccine (HEV 239, Hecolin)
Number of subjects: 20000
Study 31959609 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (hepatitis B vaccine)
Number of subjects: 20000
Study 31498799 — intervention group
Group type: EXPERIMENTAL
Intervention: FREE approach (intervention)
Number of subjects: 226
Study 31498799 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care (control)
Number of subjects: 226
Study 29215606 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient enriched breakfast bar (containing α‐Linolenic acid, l‐tyrosine, l‐theanine, vitamins, minerals and 21.5 mg of caffeine)
Number of subjects: 95
Study 29215606 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, macronutrient matched control bar
Number of subjects: 95
Study 25746294 — intervention group
Group type: EXPERIMENTAL
Intervention: 21/7‐active COC (DSG/EE+7 days EE)
Number of subjects: 146
Study 25746294 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 days of 3mg drospirenone (DRSP)/20 mcg EE, followed by 4 placebo (PBO)‐pill days (DRSP/EE+4 days PBO)
Number of subjects: 146
Study 25746294 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 days of 100 mcg levonorgestrel (LNG)/20 mcg EE, followed by 7 PBO‐pill days (LNG/EE+7 days PBO)
Number of subjects: 146
Study 23798067 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60
Study 23798067 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60
Study 21453379 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted U.S. model of pharmaceutical care (n=128)
Number of subjects: 253
Study 21453379 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control; n=125)
Number of subjects: 253
Study 19147637 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive individualised telephone based peer support
Number of subjects: 701
Study 19147637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer support)
Number of subjects: 701
Study 16766243 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour intervention using experiential and conceptual change educational approaches
Number of subjects: 48
Study 16766243 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant group
Number of subjects: 48
Study 16766243 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 48
Study 16766243 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 15327342 — intervention group
Group type: EXPERIMENTAL
Intervention: Group singing (nine 30-minute sessions)
Number of subjects: 0
Study 15327342 — intervention group
Group type: COMPARATOR
Intervention: Listening to music while exercising (control group)
Number of subjects: 0
Study 15327342 — intervention group
Group type: EXPERIMENTAL
Intervention: Group singing
Number of subjects: 0
Study 11416745 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml milk before exercise SPECT and after injection for rest SPECT acquisition (Group B) plus a standard solid and fluid meal
Number of subjects: 81
Study 11416745 — intervention group
Group type: COMPARATOR
Intervention: 200 ml milk before exercise SPECT and after injection for rest SPECT acquisition (Group A)
Number of subjects: 81
Study 9250226 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letter for mammogram or Pap smear
Number of subjects: 7077
Study 9250226 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letter and reminder placed in medical chart
Number of subjects: 7077
Study 9250226 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7077
Study 8440858 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy sessions three times weekly for 4 months, lasting 30 minutes each, consisting of functional activity and general conditioning exercises tailored to individual needs.
Number of subjects: 0
Study 8440858 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy sessions three times weekly for 4 months.
Number of subjects: 0
Study 8440858 — intervention group
Group type: COMPARATOR
Intervention: Structured social visits three times weekly to control for potential Hawthorne effects.
Number of subjects: 0
Study 8440858 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention costs and incremental health care utilization.
Number of subjects: 0
Study 3822279 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% lidocaine
Number of subjects: 53
Study 3822279 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 53
Study 29616280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0
Study 29616280 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 29616280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS)
Number of subjects: 0
Study 26730451 — intervention group
Group type: EXPERIMENTAL
Intervention: CERAMIC
Number of subjects: 92
Study 26730451 — intervention group
Group type: COMPARATOR
Intervention: POLYETHYLENE
Number of subjects: 92
Study 24956971 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5-25 mg daily, group D)
Number of subjects: 2409
Study 24956971 — intervention group
Group type: COMPARATOR
Intervention: Other antihypertensive medications (group A)
Number of subjects: 2409
Study 24956971 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (group D)
Number of subjects: 2409
Study 23276189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet (MED) for 4 months
Number of subjects: 129
Study 23276189 — intervention group
Group type: COMPARATOR
Intervention: USDA MyPyramid diet for Pregnancy and Breastfeeding (comparison diet)
Number of subjects: 129
Study 21545300 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid etching
Number of subjects: 150
Study 21545300 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin adhesives
Number of subjects: 150
Study 21545300 — intervention group
Group type: EXPERIMENTAL
Intervention: No etch + bracket
Number of subjects: 150
Study 21545300 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 150
Study 21545300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed side of teeth
Number of subjects: 150
Study 21545300 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsealed side of teeth
Number of subjects: 150
Study 21545300 — intervention group
Group type: EXPERIMENTAL
Intervention: Brackets
Number of subjects: 150
Study 18085739 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 81
Study 18085739 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 81
Study 16487390 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication (ranitidine plus cisapride)
Number of subjects: 103
Study 16487390 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant mental health consultation (IMHC)
Number of subjects: 103
Study 16487390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 16487390 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 103
Study 12871446 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg daily subcutaneous injections
Number of subjects: 85
Study 12871446 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 85
Study 12871446 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin in primary aborters (women with no previous live births)
Number of subjects: 85
Study 12871446 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin in patients with five or more miscarriages
Number of subjects: 85
Study 10831196 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 4% solution
Number of subjects: 16
Study 10831196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 16
Study 8018455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 mg kg‐1 enalaprilat (low‐dose, n = 10)
Number of subjects: 30
Study 8018455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08 mg kg‐1 enalaprilat (high‐dose, n = 10)
Number of subjects: 30
Study 8018455 — intervention group
Group type: COMPARATOR
Intervention: Saline solution as placebo (control group, n = 10)
Number of subjects: 30
Study 2659203 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% topical minoxidil
Number of subjects: 31
Study 2659203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 4582051 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 128
Study 4582051 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 128
Study 4582051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 30747745 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate administration for longer than 18 hours, given within 12 hours of delivery, maintaining a maternal serum level of 4.1 mg/dl.
Number of subjects: 0
Study 28316258 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking football
Number of subjects: 0
Study 28316258 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 0
Study 25716210 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial rhythm of ventricular fibrillation/ventricular tachycardia (VF/VT)
Number of subjects: 1655
Study 25716210 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival with good neurologic outcome
Number of subjects: 1655
Study 25716210 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial rhythm of VF/VT (exploratory secondary analysis)
Number of subjects: 1655
Study 25716210 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival with good neurologic outcome (exploratory secondary analysis)
Number of subjects: 1655
Study 25417403 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzi-cake-separated moxibustion at Guanyuan (CV 4) and Zhongji (CV 3), 20 min twice a day for 3 days before operation
Number of subjects: 60
Study 25417403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fuzi-cake-separated moxibustion)
Number of subjects: 60
Study 20882268 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 674
Study 20882268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 674
Study 19243424 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1,200 mg
Number of subjects: 400
Study 19243424 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 800 mg
Number of subjects: 400
Study 19243424 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 400 mg
Number of subjects: 400
Study 19243424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 17307536 — intervention group
Group type: EXPERIMENTAL
Intervention: Early inhaled nitric oxide (iNO) therapy
Number of subjects: 299
Study 17307536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 299
Study 15338492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 45 mg
Number of subjects: 26
Study 15338492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg
Number of subjects: 26
Study 15338492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11170945 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinafloxacin (200 mg every 12 h)
Number of subjects: 541
Study 11170945 — intervention group
Group type: COMPARATOR
Intervention: Imipenem (500 mg every 6 h)
Number of subjects: 541
Study 9824573 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT + LCT (medium chain triglycerides and long chain triglycerides)
Number of subjects: 19
Study 9824573 — intervention group
Group type: COMPARATOR
Intervention: LCT (long chain triglycerides) alone
Number of subjects: 19
Study 9824573 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT + LCT
Number of subjects: 19
Study 8824654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg q.d.s.
Number of subjects: 7
Study 8824654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 7
Study 8824654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg q.d.s.
Number of subjects: 7
Study 2382874 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine inhalation tests on day A
Number of subjects: 8
Study 2382874 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation test on day B
Number of subjects: 8
Study 2382874 — intervention group
Group type: COMPARATOR
Intervention: Methacholine inhalation tests on day C
Number of subjects: 8
Study 7362945 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic clindamycin, 150 mg 6-hourly for 5 days
Number of subjects: 0
Study 7362945 — intervention group
Group type: COMPARATOR
Intervention: Wounds treated after 4 h
Number of subjects: 0
Study 7362945 — intervention group
Group type: COMPARATOR
Intervention: All wounds treated within 4 h
Number of subjects: 0
Study 31706052 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg weekly) + daily elemental calcium (500 mg) + cholecalciferol (1000 IU)
Number of subjects: 107
Study 31706052 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily elemental calcium (500 mg) + cholecalciferol (1000 IU) only)
Number of subjects: 107